Vaxcyte
Update in progressPCVX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vaxcyte, Inc. is a clinical-stage vaccine company focused on conjugate and protein vaccines to prevent bacterial infections. Its lead program is VAX-24, a 24-valent carrier-sparing pneumococcal vaccine for invasive disease in infants, followed by VAX-31 (31-valent) for IPD in all ages, VAX-A1 for Group A Streptococcus, VAX-PG for periodontitis, VAX-GI for dysentery/Shigella, and VAX-XL, a third-generation PCV. Formerly SutroVax, renamed in 2020, based in San Carlos, CA, since 2013.
Company score
- Sentiment
- 0.44
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.25
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Grant E. Pickering M.B.A.
- Founded2013
- Employees507
- Websitevaxcyte.com
Identifiers
- ISINUS92243G1085
- FIGIBBG009PHHPL8
- LEI254900M7NMHTGASX8D95
- CUSIP92243G108
- CIK0001649094